No abstract available.
Benzimidazoles ; Diarrhea

No abstract available.
Benzimidazoles ; Diarrhea

Triclabendazole was used in treatment of 249 fascioliasis patients selected from 25 provinces including 19 Northern and 6 Southern ones. Two different doses were used for two groups: 10mg/kg/body for 226 patients, and 20mg/kg/body for 43 others, twice per day with the interval 6-8 hours from meals. Symptoms on these fascioliasis patients were found as positive ELISA test with Fasciola gigantica antigen (100%), prejudice in liver by ultrasound (87.9%), pain of liver (87.1 %), eosinophilia (63.5%), plodding (26.1 %), fever (39.8%), digestive disorder (20.1%) and positive stool examination with Fasciola egg (16.9%). Most of symptoms were decreased and disappeared within 1 month after treatment except for pain of liver in some patients that lasted longer and disappeared within 6 to 12 months after treatment. The cure rate was 92.9% for 1 month after treatment, 95.2% for 3 months after treatment and 100% for 6 months after treatment. Ultrasound prejudice in liver decreased and disappeared 80.9% for 1 month, 92.6% for 3 months, 96.3% for 6 months and 100% for 12 months after treatment. Eosinophilia rate returned to normal of 90.7% for 6 months and 100% for 12 months after treatment. ELISA test with F. gigantica antigen become negative of 89.4% for 6 months and 100% for 12 months. GOT, GPT, urea and creatinin tests had not pathological change by 1 month using triclabendazole. Side effect of triclabendazole was inconsiderable and disappeared without medical treatment. Triclabendazole may be recommended in treatment for fascioliasis in Vietnam with doses of 10 or 20 mg/kg of body weight.
Fasciolidae ; Therapeutics ; Benzimidazoles

Human fascioliasis has recently been widely found in many regions of Vietnam confirmed by clinical and laboratory examinations. Therapeutic efficacy of the specific treatment drug for this disease - triclabendazole (provided by WHO) - was investigated in a study conducted in the hospital for tropical diseases, Ho Chi Minh city from November 2004 to August 2005. A total number of 53 patients treated with single dose of triclabendazole 10 mg/kg of body weight were found to have good compliance. All clinical symptoms disappeared within 24 hours of drug administration and three days later the patients were allowed to discharge with the good health status: pinky face, no abdominal pain and fever, normal vital signs, and good general status. All the patients were requested to return to hospital for re-checking after three months. However, only 18 of them had followed the request due to the objective reasons. The returned ones were found to have good health state with no resurgent clinical features and normal laboratory findings except for a slow decrease of antibody titer. The remaining patients were followed up via telephone and mails showed good health status. Triclabendazole was found to be a good anti-fascioliasis drug with high safety and efficacy and low side effects, and is recommended to widely use in treatment for fascioliasis.
Fascioliasis ; Therapeutics ; Benzimidazoles

No abstract available.
Benzimidazoles ; Quinuclidines ; Tetrahydroisoquinolines ; Solifenacin Succinate

No abstract available.
Benzimidazoles ; Quinuclidines ; Tetrahydroisoquinolines ; Solifenacin Succinate

No abstract available.
Benzimidazoles ; Blood Pressure ; Stroke ; Tetrazoles

No abstract available.
Benzimidazoles ; Diarrhea ; Humans ; Irritable Bowel Syndrome ; Male

Humans ; Child ; Neurofibromatosis 1/drug therapy* ; Benzimidazoles/therapeutic use*

PURPOSE: Combination therapy with aprepitant, serotonin receptor antagonist, and steroids improves the complete response rate of both acute and delayed chemotherapy-induced nausea and vomiting (CINV). However, it is not known whether ramosetron is suitable for administration in combination with aprepitant. Therefore, we conducted a multicenter, open-label, prospective, phase II study in order to assess the efficacy and tolerability of combination therapy with ramosetron, aprepitant, and dexamethasone (RAD) for prevention of cisplatin-based CINV in chemotherapy-naive patients with solid cancers. MATERIALS AND METHODS: Forty-one patients with various solid cancers (31 male and 10 female; median age, 59 years) who received treatment with highly emetogenic chemotherapy (median cisplatin dose, 70 mg/m2; range 50 to 75 mg/m2) were enrolled in this study. Oral aprepitant (125 mg on day 1; 80 mg on days 2 and 3), intravenous ramosetron (0.6 mg on day 1), and oral dexamethasone (12 mg on day 1; 8 mg on days 2-4) were administered for prevention of CINV. RESULTS: The complete response (no emesisand retching and no rescue medication) rate was 94.9% in the acute period (24 hours post-chemotherapy), 92.3% in the delayed period (24-120 hours post-chemotherapy), and 92.3% in the overall period (0-120 hours). The absolute complete response (complete response plus no nausea) rate was 74.4% in the acute period, 51.3% in the delayed period, and 46.2% in the overall period. There were no grade 3 or 4 toxicities related to these antiemetic combinations. CONCLUSION: RAD regimen is a safe and effective antiemetic treatment for prevention of CINV in patients receiving highly emetogenic chemotherapy.
Benzimidazoles ; Cisplatin ; Dexamethasone ; Humans ; Male ; Morpholines ; Nausea ; Prospective Studies ; Serotonin ; Steroids ; Vomiting